Living With Cancer

【知癌知癒】 同路人故事 • 樂觀面對挑戰

Living With Cancer

Preparing for Future Challenges in Geriatric Surgical Oncology

Living With Cancer

Atezolizumab/Bevacizumab Moves Forward in Metastatic Renal Cell Carcinoma

New Drug Info

ICML 2017: ADCT-402 Demonstrates Encouraging Antitumor Activity in Relapsed/Refractory Non-Hodgkin Lymphoma

Living With Cancer

【知癌知癒】 以選擇性體內放療對付肝癌

Living With Cancer

NCCN Guidelines® Compliance for Chest CT May Reduce False Positives and Decrease Health-Care Spending in Breast Cancer

Living With Cancer

Weight Management and Physical Activity in Cancer Care:From Research to Real World

Living With Cancer

Cancer Risk May Be Higher Among Holocaust Survivors

Living With Cancer

Classifying Gastric Cancers by Subtype May Provide Tailored Treatment Options

Living With Cancer

Genetic Study Identifies Susceptibility Loci Modifying Risk for Breast Cancer After Radiation Therapy for Childhood Cancer

Living With Cancer

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.

Living With Cancer

St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment.

Living With Cancer

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In this trial, we investigated whether pertuzumab, when added to adjuvant trastuzumab and chemotherapy, improves outcomes among patients with HER2-positive early breast cancer.

Living With Cancer

Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).

The addition of pertuzumab leads to increased pCR rates for all HER2+ patient groups except for the BluePrint basal-type patients. This better response was most pronounced for the BluePrint luminal-type patients.

Living With Cancer

【知癌知癒】

肝癌治療你知幾多?


Next